465 related articles for article (PubMed ID: 25928069)
1. Designer drugs 2015: assessment and management.
Weaver MF; Hopper JA; Gunderson EW
Addict Sci Clin Pract; 2015 Mar; 10(1):8. PubMed ID: 25928069
[TBL] [Abstract][Full Text] [Related]
2. Bath salts and synthetic cathinones: an emerging designer drug phenomenon.
German CL; Fleckenstein AE; Hanson GR
Life Sci; 2014 Feb; 97(1):2-8. PubMed ID: 23911668
[TBL] [Abstract][Full Text] [Related]
3. Synthetic cathinones: chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as "bath salts" or "plant food".
Coppola M; Mondola R
Toxicol Lett; 2012 Jun; 211(2):144-9. PubMed ID: 22459606
[TBL] [Abstract][Full Text] [Related]
4. Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling.
Liechti M
Swiss Med Wkly; 2015; 145():w14043. PubMed ID: 25588018
[TBL] [Abstract][Full Text] [Related]
5. Toxicology and management of novel psychoactive drugs.
Kersten BP; McLaughlin ME
J Pharm Pract; 2015 Feb; 28(1):50-65. PubMed ID: 25261428
[TBL] [Abstract][Full Text] [Related]
6. Designer drugs in psychiatric practice - a review of the literature and the recent situation in Hungary.
Szily E; Bitter I
Neuropsychopharmacol Hung; 2013 Dec; 15(4):223-31. PubMed ID: 24380963
[TBL] [Abstract][Full Text] [Related]
7. Designer Drug (DD) abuse in Poland; a review of the psychoactive and toxic properties of substances found from seizures of illegal drug products and the legal consequences thereof. Part 1--cannabinoids and cathinones.
Biliński P; Hołownia P; Kapka-Skrzypczak L; Wojtyła A
Ann Agric Environ Med; 2012; 19(4):857-70. PubMed ID: 23311820
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States.
Spiller HA; Ryan ML; Weston RG; Jansen J
Clin Toxicol (Phila); 2011 Jul; 49(6):499-505. PubMed ID: 21824061
[TBL] [Abstract][Full Text] [Related]
9. Synthetic drugs of abuse.
Tamama K
Adv Clin Chem; 2021; 103():191-214. PubMed ID: 34229850
[TBL] [Abstract][Full Text] [Related]
10. Baths salts, spice, and related designer drugs: the science behind the headlines.
Baumann MH; Solis E; Watterson LR; Marusich JA; Fantegrossi WE; Wiley JL
J Neurosci; 2014 Nov; 34(46):15150-8. PubMed ID: 25392483
[TBL] [Abstract][Full Text] [Related]
11. GHB and synthetic cathinones: clinical effects and potential consequences.
Karila L; Reynaud M
Drug Test Anal; 2011 Sep; 3(9):552-9. PubMed ID: 21960540
[TBL] [Abstract][Full Text] [Related]
12. New Drugs of Abuse and Withdrawal Syndromes.
Andrabi S; Greene S; Moukaddam N; Li B
Emerg Med Clin North Am; 2015 Nov; 33(4):779-95. PubMed ID: 26493523
[TBL] [Abstract][Full Text] [Related]
13. "Not for human consumption": a review of emerging designer drugs.
Musselman ME; Hampton JP
Pharmacotherapy; 2014 Jul; 34(7):745-57. PubMed ID: 24710806
[TBL] [Abstract][Full Text] [Related]
14. Spice, bath salts, and the U.S. military: the emergence of synthetic cannabinoid receptor agonists and cathinones in the U.S. Armed Forces.
Loeffler G; Hurst D; Penn A; Yung K
Mil Med; 2012 Sep; 177(9):1041-8. PubMed ID: 23025133
[TBL] [Abstract][Full Text] [Related]
15. Synthetic cathinones ("bath salts").
Banks ML; Worst TJ; Rusyniak DE; Sprague JE
J Emerg Med; 2014 May; 46(5):632-42. PubMed ID: 24565885
[TBL] [Abstract][Full Text] [Related]
16. "Legal highs" - new players in the old drama.
Zawilska JB
Curr Drug Abuse Rev; 2011 Jun; 4(2):122-30. PubMed ID: 21711229
[TBL] [Abstract][Full Text] [Related]
17. Stimulant and Designer Drug Use: Primary Care Management.
Klega AE; Keehbauch JT
Am Fam Physician; 2018 Jul; 98(2):85-92. PubMed ID: 30215997
[TBL] [Abstract][Full Text] [Related]
18. Designer Drugs 2.0.
Huestis MA; Tyndale RF
Clin Pharmacol Ther; 2017 Feb; 101(2):152-157. PubMed ID: 28084644
[TBL] [Abstract][Full Text] [Related]
19. New and Emerging Illicit Psychoactive Substances.
Graddy R; Buresh ME; Rastegar DA
Med Clin North Am; 2018 Jul; 102(4):697-714. PubMed ID: 29933824
[TBL] [Abstract][Full Text] [Related]
20. New synthetic drugs in addictovigilance.
Chavant F; Boucher A; Le Boisselier R; Deheul S; Debruyne D
Therapie; 2015; 70(2):167-89. PubMed ID: 25858573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
